Biotech

All Articles

Bicara, Zenas find IPOs to push late-phase properties toward market

.Bicara Rehabs and Zenas Biopharma have supplied new inspiration to the IPO market with filings that...

Genentech to finalize cancer cells immunology study division

.Genentech will certainly shut its own cancer immunology analysis department, as well as unit head a...

Kezar loses solid lump but to verify its own truly worth in period 1 trial

.Kezar Life Sciences is actually losing its dim stage 1 solid cyst drug as the biotech goes all-in o...

Acelyrin loses izokibep, drops 3rd of staff

.In spite of izokibep keeping its own newfound winning touch in the facility, Acelyrin is actually n...

Rivus' stage 2 obesity-related cardiac arrest test hits endpoint

.Rivus Pharmaceuticals has plumped up the prospects of its own fat-busting, muscle-sparing medicatio...

Ovid halts preclinical job, IV plan after soticlestat stop working

.Ovid Therapy actually uncovered last month that it was actually trimming back its own headcount as ...

Eli Lilly opens up $700M nucleic acid R&ampD facility in Boston ma Seaport

.Eli Lilly has actually opened a $700 million R&ampD facility in the Boston ma Port, boosting its ow...

Boundless Biography makes 'small' discharges 5 months after $100M IPO

.Merely five months after safeguarding a $one hundred million IPO, Vast Biography is actually laying...

Halda's $126M will definitely evolve 'secure and kill' lump drugs

.The initial phases of oncology R&ampD aren't short of interesting brand-new methods, and also Halda...

Lykos 'disappointments' not disclosing research study violations along with publisher

.Psychopharmacology has pulled 3 short articles about midstage clinical trial information determinin...